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ABSTRACT: Fosfomycin [(1R,2S)-epoxypropylphosphonic acid] is a simple phosphonate found to have
antibacterial activity against both Gram-positive and Gram-negative microorganisms. Early resistance to
the clinical use of the antibiotic was linked to a plasmid-encoded resistance protein, FosA, that catalyzes
the addition of glutathione to the oxirane ring, rendering the antibiotic inactive. Subsequent studies led to
the discovery of a genomically encoded homologue in the pathogenPs udomonas aeruginosa.The proteins
are Mn(II)-dependent enzymes where the metal is proposed to act as a Lewis acid stabilizing the negative
charge that develops on the oxirane oxygen in the transition state. Several simple phosphonates, including
the antiviral compound phosphonoformate (Ki ) 0.4( 0.1µM, Kd ≈ 0.2µM), are shown to be inhibitors
of FosA. The crystal structure of FosA fromP. aeruginosawith phosphonoformate bound in the active
site has been determined at 0.95 Å resolution and reveals that the inhibitor forms a five-coordinate complex
with the Mn(II) center with a geometry similar to that proposed for the transition state of the reaction.
Binding studies show that phosphonoformate has a near-diffusion-controlled on rate (kon ≈ 107-108 M-1
s-1) and an off rate (koff ) 5 s-1) that is slower than that for fosfomycin (koff ) 30 s-1). Taken together,
these data suggest that the FosA-catalyzed reaction has a very early transition state and phosphonoformate
acts as a minimal transition state analogue inhibitor.
Fosfomycin [(1R,2S)-epoxypropylphosphonic acid,1] is
a natural product with broad-spectrum antimicrobial activity
against both Gram-positive and Gram-negative microorgan-
isms (1, 2). The drug inhibits the enzyme UDP-N-acetyl-
glucosamine-3-enolpyruvyltransferase (MurA), which cata-
lyzes the first committed step in microbial cell-wall
biosynthesis (3-5). Properly formulated, the drug has good
bioavailability, is eliminated virtually unmetabolized via renal
excretion, and exhibits very low toxicity with few side
effects. The drug is currently used in a single-dose oral
treatment for acute uncomplicated lower urinary tract infec-
tion (6, 7). It has also been suggested that large doses of
fosfomycin are effective against vancomycin-resistant en-
terococci (8).
Shortly after introduction of fosfomycin in the clinic, a
plasmid-mediated resistance to the antibiotic was observed
in clinical isolates from patients treated with the drug (9-
11). Subsequent investigations established that the resistance
gene encoded a 16 kDa polypeptide (FosA) that catalyzed
the addition of glutathione (GSH)1 to the antibiotic (Scheme
1), rendering it inactive (12, 13). FosA is a Mn(II)- and K+-
dependent homodimeric enzyme (14-16) that belongs to the
vicinal oxygen chelate (VOC) superfamily of metallo-
enzymes that includes glyoxalase I, methylmalonyl-CoA
epimerase, and extradioldioxygenases (17, 18). Close rela-
tives of FosA also appear in microbial genomes and may be
responsible for intrinsic resistance of many microorganisms
to the antibiotic. For example, thePA1129 gene from
Pseudomonas aeruginosaencodes a FosA protein that has
catalytic properties very similar to those of the plasmid-
encoded enzyme (19). In addition, theyndN gene from
Bacillus subtilishas been demonstrated to confer resistance
to the antibiotic by catalyzing the addition ofL-cysteine to
the oxirane ring in a Mg2+-dependent reaction (20).
The FosA enzyme is a dimer composed of pairedâRâââ
motifs that form a cupped-shaped metal ion binding site as
illustrated in Figure 1 (19). The two subunits have a domain-
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swapped arrangement so that each Mn(II) binding site is
formed fromâRâââ motifs from opposing subunits. The K+
ion is accommodated in a loop located 6.5 Å from the
Mn(II) center.
Numerous lines of evidence suggest that the Mn(II) center
of FosA participates directly in the catalytic mechanism (14,
16, 19, 22, 23). The single most convincing piece of evidence
is the crystal structure of the substrate complex, which shows
that the phosphonyl group of fosfomycin is coordinated to
the metal positioning the oxirane oxygen just outside the
inner coordination sphere as illustrated in Figure 2. The
structure clearly suggests that the Mn(II) ion acts as a Lewis
acid in facilitating the addition of GSH at C-1. In the
substrate-bound ground state, the metal ion has a formal four-
coordinate geometry that is expected to become five-
coordinate as the carbon-oxygen bond begins to break in
the transition state (Figure 2B).
Plasmid-encoded and genomically encoded fosfomycin
resistance proteins constitute a serious impediment to the
efficacy of the antibiotic toward pathogenic microorganisms.
The development of inhibitors of these resistance proteins
represents an opportunity to expand the clinical utility of
the drug. In this paper, we present evidence that the antiviral
compound, phosphonoformate (3), is an effective inhibitor
of FosA and superior to other simple phosphonates. The
kinetic and spectroscopic properties of the inhibitor complex,
as well as its crystal structure determined at a resolution of
0.95 Å, suggest that3 functions as a minimal transition state
inhibitor of FosA.
EXPERIMENTAL PROCEDURES
Materials.Glutathione, glutathione sulfonate, and protease
inhibitor solution were purchased from Sigma (St. Louis,
MO). The plasmid-encoded FosA and the FosA fromP.
aeruginosa were expressed and purified as previously
described (14, 19). Acetonitrile (HPLC grade) was purchased
from EM Science (Gibbstown, NJ).PfuTurboDNA poly-
merase was purchased from Stratagene (La Jolla, CA) and
Quick T4 DNA Ligase from New England BioLabs Inc.
(Beverly, MA). Phosphonoacetic acid, 2-carboxyethylphos-
phonic acid, and tris(trimethylsilyl) phosphite were from
Aldrich (Milwaukee, WI). Acetyl chloride and diethyl ether
were from Fisher. Triethylphosphonoformate was from
Avocado Research Chemicals Ltd. AG1-X8 resin was from
Bio-Rad. All materials were used without further purification.
All the solutions were prepared and used on the same day.
Synthesis of Phosphonoformate. Phosphonoformate (3)
was prepared from triethylphosphonoformate by a previously
reported method [Jakupovic, E.,et al. (1997) U.S. Patent
5591889]. Triethylphosphonoformate (10 g, 48 mmol) was
added to a solution of 11.42 g (285 mmol) of sodium
hydroxide in 90 mL of water at 50°C. The solution was
heated to 90°C. After being refluxed for 1 h, the reaction
mixture was cooled to 20°C. Phosphonoformate was then
filtered from the reaction mixture using a Buchner funnel
fitted with Whatman #1 filter paper. The product was
recrystallized from water and lyophilized to dryness.
Synthesis of Acetylphosphonate.Acetylphosphonic acid
was synthesized following methods previously described (24,
25). Tris(trimethylsilyl) phosphite was slowly added to a
2-fold excess of acetyl chloride in a flask immersed in an
ice/EtOH bath. The mixture was stirred for at least 2 h on
ice and then stirred at room temperature overnight. After
removal of the volatile silane products, the pH of the solution
was adjusted to 4 with NaOH. The reaction mixture was
extracted with diethyl ether several times. The aqueous layer
containing the product was then taken to dryness by
lyophilization: 1H NMR (300.1 MHz, D2O) δ 2.22 (d,JPCH
) 3.72 Hz);13C NMR (75.5 MHz, D2O) δ 30.6 (d,JCP )
43.8 Hz), 228.6 (d,JCCP ) 157.6 Hz).
Enzyme Assay and Inhibition. Enzyme assays were carried
out as previously described (14). In a typical reaction
mixture, the enzyme (60-150 nM) was incubated with 100
mM KCl, 50 µM MnCl2, and 15 mM GSH in 20 mM
HEPES/TMA (pH 8.0) at 25°C in the presence of 1, 2, 3,
or 4 mM disodium fosfomycin and varying concentrations
of phosphonoformate, acetylphosphonic acid, phosphonoace-
tic acid, or 2-carboxyethylphosphonic acid. Reactions were
quenched; 1.0 mM valine was added as an internal standard,
and the mixture was reacted with the Waters AccQFluor
reagent and analyzed by reversed-phase HPLC. Inhibition
data were analyzed as a Dixon plot (1/V vs [I]) to determine
KI (26).
FIGURE 1: Ribbon diagram of the structure of FosA (PA1129) from
P. aeruginosataken from ref19. The Mn(II) and K+ ions are
illustrated as purple and green spheres, respectively. The image
was created with PyMOL (21).
FIGURE 2: (A) Schematic of the interaction of fosfomycin with
the Mn(II) center of FosA derived from the crystal structure at a
resolution of 1.19 Å (19). The metal coordination is formally four-
coordinate with a highly distorted tetrahedral geometry. The distance
between the oxirane oxygen and Mn(II) is 2.35 Å. (B) Proposed
transition state for the addition of GS- to fosfomycin. The metal
is envisioned to approach a five-coordinate trigonal bipyramidal
geometry.
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Titration of FosA with1 and3. A solution of 0.1µM FosA
in the presence of 50µM MnCl2 was prepared in 20 mM
TMA/HEPES (pH 8.0) containing 100 mM KCl which had
been filtered through a 0.2µM filter. A solution of 50µM
MnCl2 in buffer was similarly prepared. Phosphonates were
added to both solutions incrementally while monitoring the
change in fluorescence. Titration measurements were made
in triplicate on a SPEX Fluorolog-3 spectrofluorimeter (Jobin
Yvon Horiba, Edison, NJ) in the constant-wavelength mode.
Solutions were excited at 275 nm (3 mm slit width), and
emission measurements were taken at 330 nm (2 mm slit
width). After data were corrected for fluorescence of the
buffer solution, data were averaged and fit as the absolute
value of the change in fluorescence to eq 1
Stopped-Flow Analysis of Binding Kinetics. The PA1129
FosA incubated with MnCl2 and3 in 20 mM HEPES/TMA
(pH 8.0) was mixed with varying concentrations of fos-
fomycin in an Applied Photophysics SX17 stopped-flow
spectrometer in absorbance mode. The change in absorbance
at 245 nm was monitored as a function of time; 1000 data
points were collected in 100 ms using the oversampling
method. Concentrations in the observation cell were as
follows: 5 µM FosA, 50µM MnCl2, 100 mM K+, 25 µM
2, and 5, 10, 15, and 20 mM1. Data were fitted to a single-
exponential, floating end point equation using the instrument
software to obtainkobs. The first 2 ms of data were omitted
from the data analysis. The off rate for1 was measured in
a similar manner by trapping with3.
Crystallographic Data Collection.Crystals of the FosA
enzyme fromP. aeruginosawere obtained at 22°C from
40% pentaerythritol propoxylate 629 (PEP629) and 80 mM
K2HPO4 (pH 7.0) in the presence 0.8 mM Mn2+ and 0.8 mM
fosfomycin as previously described (19). The crystals dif-
fracted quite well but contained phosphate bound in the active
site. The crystals were transferred to a new drop containing
40% PEP629, 40 mM potassium chloride, 40 mM phospho-
noformate (pH 7.0), and 0.8 mM manganese(II) chloride.
These crystals were allowed to soak for 1 h before they were
mounted for screening at Vanderbilt with an RU-200H
rotating anode source and a RaxisIV image plate. All crystals
were frozen directly from the drop, as the mother liquor
provided sufficient cryroprotection against the formation of
ice. The incubation with inhibitor had no apparent effect on
the resolution.
A high-resolution data set was collected at-180°C with
an ADSC Quantum 4 detector at the BioCARS beamline 14
BMC at the Advanced Photon Source (Argonne National
Laboratory, Argonne, IL). The data were collected in two
passes, each containing 100, 1° oscillation images that
covered the same range of crystal orientation. The high-
resolution reflections were collected in the first pass with a
crystal-to-detector distance of 70 mm and an exposure time
of 20 s. The second pass, to obtain the lower-resolution
reflections, was taken with a crystal-to-detector distance of
150 mm and an exposure time of 2 s. The data were scaled
and processed with SCALEPACK and DENZO (27). A
summary of the data collection and processing statistics is
presented in Table 1.
Crystals grown in the presence of product2 were obtained
from buffered [100 mM MES (pH 6.5)] 1.8 M ammonium
sulfate at 25°C. Data were collected at-160 °C with a
Rigaku RU200H source equipped with Yale mirrors and a
RaxisIV imaging plate diffractometer. The data were pro-
cessed with SCALEPACK and DENZO.
Crystallographic Refinement. Structure refinement calcula-
tions for the phosphonoformate complex were carried out
with SHELXL (28). The structure of the phosphate complex
at 1.35 Å resolution (PDB entry 1LQK) was used for an
initial round of rigid body refinement giving anRwork of
38.0% and anRfree of 37.5%. SHELXL was then used for a
round of water divining, followed by several cycles of
manual water addition and removal, the placement of residues
with alternate conformations, and the placement of the
inhibitor in the model, giving anRwork of 20.0% and anRfree
of 22.4%. A final round of refinement with anisotropic
temperature factors and riding hydrogen atoms resulted in
an Rwork of 13.3% and anRfree of 16.1%. The statistics for
validation of the final model are given in Table 1.
The structure of the protein from the ammonium sulfate
crystal form had significantly different unit cell dimensions
and was phased by molecular replacement. The starting
|∆F| )
-[-(Kd + [P] + Fmax) + x(Kd + [P] + Fmax)2 - 4[P]Fmax2 ]
(1)
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model consisted of the PA1129 FosA stripped of all
nonprotein atoms. MOLREP (29) was then used to orient
the model in the ammonium sulfate crystal form. This gave
an initial Rcrys of 37% and a correlation coefficient of 0.65,
indicating the search was successful. To reduce model bias,
the new model was run through a round of simulated
annealing in CNS (30), giving anRcrys of 30% and anRfree
of 35%. Inspection of the active site indicated that no product
was present; instead, there was a sulfate ion coordinated to
the Mn(II) center. The model was iteratively refined using
O (31) for visualization and model adjustment and REFMAC
(32) for refinement. The Mn(II) ions, sulfate ions, and water
molecules [added automatically with APR/warp (33)] were
included in the subsequent rounds of refinement. Data
collection and final refinement statistics are given in Table
1.
RESULTS
Inhibition of FosA with Simple Phosphonates. The original
crystal structure of FosA (19) in the presence of1 revealed
extensive interactions between the phosphonyl group of
fosfomycin and the active site, including coordination to the
Mn(II) center and electrostatic or hydrogen bonding interac-
tions with K40, S94, Y100, R119, and the K+ ion, suggesting
that simple phosphonates might be effective competitive
inhibitors against fosfomycin. This notion was confirmed by
a survey of several such molecules shown in Figure 3. The
inhibition results appear to correlate with the geometry and
electrostatics that are necessary for optimum formation of a
bidentate chelate complex with the metal. The most avid
inhibitor, 3, also more closely resembles the proposed early
transition state for the reaction illustrated in Figure 2.
Compound3 is also a good inhibitor of the plasmid-encoded
FosA (Tn2921) with aKi of 0.69 ( 0.08 µM.
Kinetics of Binding of Fosfomycin and Phosphonoformate.
The binding of 1 or 3 to the FosA‚Mn(II) complex is
accompanied by similar but distinct spectral changes in the
protein as illustrated in Figure 4A. The spectral differences
were exploited in an effort to obtain kinetic information about
the binding of substrate and inhibitor. Although initial
experiments indicated that the sum of the on and off rates
for 1 or 3 was too large to be directly measured by rapid
mixing techniques, it was possible to exploit the difference
in the ∆ε245 values for the two complexes to obtain thekoff
for 3 from the FosA‚Mn(II) ‚K+‚3 complex and thekoff for 1
from the FosA‚Mn(II) ‚K+‚1 complex. When the preformed
FosA‚Mn(II) ‚K+‚3 complex was rapidly mixed with a large
excess of1, the kinetics for formation of the FosA‚Mn(II) ‚
K+‚1 complex could be followed by the increase in absor-
bance at 245 nm as illustrated in Figure 4B. The formation
of the FosA‚Mn(II) ‚K+‚1 complex followed single-expo-
nential kinetics with akobs of 5 s-1 that was independent of
1 concentration between 5 and 20 mM. The kinetic behavior
is consistent with the rapid trapping, by1, of the ternary
FosA‚Mn(II)‚K+ complex formed upon dissociation of3. The
reciprocal experiment in which the FosA‚Mn(II) ‚K+‚1
complex was rapidly mixed with a high concentration of3
was accompanied as expected by a rapid decrease in
absorbance at 245 nm with akobs of 30 s-1 (Figure 4C).
FIGURE 3: Inhibitors used in this study. For phosphonoformate (3),
Ki ) 0.41 ( 0.09 µM. For acetylphosphonate (4), Ki ) 18 ( 2
µM. For phosphonoacetate (5), Ki ) 10 ( 1 µM. For 2-carboxy-
ethylphosphonate (6), Ki > 100 µM.
FIGURE 4: (A) UV difference spectra of the complexes: (- - -)
FosA‚Mn(II) ‚2 - FosA‚Mn(II) (∆ε245 ) -1690 M-1 cm-1) and
(s) FosA‚Mn(II) ‚3 - FosA‚Mn(II) (∆ε245 ) -4560 M-1 cm-1).
(B) Change inA245 on rapid mixing of 5µM FosA‚Mn(II) ‚K+‚3
with 10 mM fosfomycin. The solid line is a fit of the data to a
single-exponential equation with akobs of 5.06 ( 0.02 s-1. The
bottom trace is the residual to the fit. (C) Change inA245 upon
rapid mixing of the FosA‚Mn(II) ‚K+‚1 complex with 5 mM
phosphonoformate. The solid line is a fit of the data to a single-
exponential equation with akobsof 29 ( 3 s-1. The bottom trace is
the residual to the fit.
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In principle, the changes in the UV spectra of the
complexes could be exploited to obtain equilibrium dissocia-
tion constants for1 and3. Unfortunately, the concentrations
of enzyme required for monitoring titrations in the UV were
in excess of the estimatedKd values for the complexes.
However, the complexes were also found to have significant
differences in their fluorescence spectra as illustrated in
Figure 5A. The FosA‚Mn(II) ‚K+‚1 complex exhibits a 37%
decrease in fluorescence at 330 nm when compared to the
FosA‚Mn(II) ‚K+ complex. In addition, the FosA‚Mn(II) ‚K+‚
3 complex exhibits a blue shift of the emission band to 326
nm.
The fluorescence titrations of the FosA‚Mn(II) ‚K+ com-
plex with 1 and 3 at a low concentration (0.1µM) of the
protein are illustrated in Figure 5B. The extracted estimates
of theKd values indicate that, in the absence of GSH,3 binds
only ∼4-fold more tightly than the substrate. TheKd value
of 0.2 µM for 3 is in reasonable agreement with theKi of
0.4 µM obtained in the inhibition experiments.
High-Resolution Structure of the Inhibitor Complex. The
high-resolution structure of the FosA‚Mn(II) ‚3 inhibitor
complex is quite similar to that of the substrate complex
previously determined, with an rmsd on CR positions of 0.29
Å. The electron density of the inhibitor reveals that it forms
a tight bidentate chelate complex with the Mn(II) center
(Figure 6) with very good trigonal bipyramidal geometry.
The angular structural parameter for describing trigonality
is high (τ ) 0.92), where a perfect trigonal bipyramid has a
τ of 1.0 (34). The two histidine ligands from the protein and
a phosphonate oxygen from the inhibitor occupy the equato-
rial positions, while the glutamate and the carboxylate group
of 3 are axial ligands. The principal difference in the
coordination geometry of the substrate and inhibitor com-
plexes is the Mn(II)-O distance between the neutral oxirane
oxygen ligand in the substrate complex as shown in Figure
7.
The side chains of four residues (T9, S94, Y100, and
R119) participate in binding both inhibitor and substrate as
illustrated in Figure 8. The only significant difference in the
structure of the protein in the substrate and inhibitor
complexes is the position of Y62, which is pointed away
from fosfomycin in the substrate complex and swings toward
phosphonoformate in the inhibitor complex where its hy-
droxyl group is within hydrogen bonding distance (2.58 Å)
of the phosphonyl group of3. The hydroxyl group of Y62
in the substrate complex is within hydrogen bonding distance
of two water molecules. The recruitment of Y62 to interact
directly with the inhibitor may be a consequence of additional
negative charge in the complex. It is possible that the
difference in the position of Y62 in the two complexes gives
rise, at least in part, to their different spectral properties in
the UV.
Structure of FosA Crystallized from Ammonium Sulfate.
The second crystal form of FosA obtained from ammonium
sulfate was determined at a resolution of 2.25 Å. The overall
structure is quite close to that of the FosA‚Mn(II) ‚1 complex
with an rmsd on CR positions of 0.47 Å. Crystal lattice
contacts in this crystal form do not appear to block the
approach to the active site. However, electron density maps
for crystals grown in the presence of either GSH or the
product, 2, showed no electron density that could be
FIGURE 5: (A) Fluorescence emission spectra of the FosA‚Mn(II) ‚
K+ (s), FosA‚Mn(II) ‚K+‚1 (- - -), and FosA‚Mn(II) ‚K+‚3 (- - -
) complexes with excitation at 275 nm. (B) Fluorescence titrations
of the FosA‚Mn(II) complex (2) and3 (9). The solid lines are fits
of the data to eq 1 with dissociation constants of 0.74( 0.01µM
for 1 and 0.17( 0.01 µM for 3.
FIGURE 6: Stereoview of the 2Fo - Fc electron density map of the FosA‚Mn(II) ‚3 complex at 0.95 Å resolution and contoured at 2σ. The
Mn(II) and K+ ions are shown as purple and green spheres, respectively. The figure was generated with PyMOL (21).
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attributed to these species. Rather, a sulfate ion is found
coordinated to the Mn(II) center at a position very close to
that occupied by the phosphonyl group in the structures of
the FosA‚Mn(II) ‚1 and FosA‚Mn(II) ‚3 complexes (Figure
9). In addition, the K+ loop in this structure is occupied by
NH4+, which is also known to activate the enzyme (16). It
appears that the high concentration of (NH4)2SO4 prevents
formation of the substrate or product complexes.
The Mn(II) ion in this structure is four-coordinate with a
highly distorted tetrahedral geometry that was previously
observed in a phosphate complex (19). Each oxygen of the
sulfate ion has hydrogen bonding or electrostatic interactions
with neighboring groups, including the Mn(II) ion, the
hydroxyl groups of Y62 and S94, and water molecules that
bridge the hydroxyl group of Y39 and the carboxylate of
E110.
DISCUSSION
Coordination Geometry of Mn(II) and Mechanism of FosA.
The Mn(II) centers of the phosphate (19) and sulfate
complexes of FosA exhibit a rarely observed four-coordinate
geometry where the tetrahedral anions occupy the site that
accommodates the phosphonyl groups of1 and 3. It is
interesting to note that a sulfate ion is observed at the same
position in the crystal structure of the plasmid-encoded
(Tn2921) apoFosA obtained in the absence of Mn(II) (35).
Thus, a tetrahedral anion binding site exists even in the
absence of metal. The substrate complex approaches a five-
coordinate trigonal bipyramidal geometry with the oxirane
oxygen∼0.2 Å farther from the metal than might be expected
for a neutral oxygen ligand. In contrast, the phosphono-
formate complex has almost perfect trigonal bipyramidal
geometry. We conclude that the primary determinants of
substrate recognition are the interactions developed between
the phosphonyl group of1 and the enzyme, including the
Mn(II) and K+ ions. Recognition of the transition state
appears to be driven by the change to a more favorable five-
coordinate geometry of the Mn(II) center.
Kinetics of Binding Fosfomycin and Phosphonoformate.
The dissociation constant of 0.2µM andkoff of 5 s-1 suggest
that the binding of3 occurs near the diffusion limit;kon )
koff/Kd ≈ 107-108 M-1 s-1. Thekoff of 30 s-1 and theKd of
0.7 µM are consistent with a diffusion-controlled binding
of 1 as well. The one clearly measurable difference in the
equilibrium binding of3 is the smaller rate constant for
dissociation of the bidentate chelate.
Inhibition of FosA by Phosphonates. Several simple
phosphonates are modestly effective inhibitors of the FosA
enzyme encoded in the genome ofP. aeruginosa. Com-
pounds3-5 were chosen as possible transition state ana-
logues of the addition reaction based on the original
suggestion that the Mn(II) center acts as a Lewis acid to
facilitate breaking of the C-O bond of the oxirane (14, 19).
Oxirane ring opening reactions typically occur with early
transition states so that the geometry of the proposed five-
membered chelate ring (Figure 2B) is very close to that
FIGURE 7: Internuclear distances in angstroms between heavy atoms
in (A) the FosA‚Mn(II) ‚1 complex and (B) the FosA‚Mn(II) ‚3
complex.
FIGURE 8: Local superposition of the FosA‚Mn(II)‚3 complex (blue)
with the substrate FosA‚Mn(II) ‚1 complex. The superposition was
done using only the positions of the Mn(II) and protein ligands
H7, H64, and E110 (not shown). S94, which is also within hydrogen
bonding distance of the phosphonyl group, is not shown for clarity.
Note the repositioning of the Y62 side chain in the inhibitor
complex.
FIGURE 9: Local superposition of the structures of the sulfate (blue)
and phosphonoformate complexes of FosA. The superposition was
done using the Mn(II) positions and metal ligands from the protein
[H7, H64, and E110 (not shown)]. The displacement of the sulfur
of the sulfate from the position of the phosphorus in3 is 0.4 Å.
Inhibition of FosA by Phosphonoformate Biochemistry, Vol. 43, No. 43, 200413671
observed in the complex with3. Moreover, it is evident from
the superposition of the fosfomycin and phosphonoformate
structures (Figure 7) that the carboxylate oxygen of the
inhibitor and the oxirane oxygen of the substrate occupy
nearly the same position. Phosphonoacetate,5, with the
chelate ring expanded by a methylene group, binds∼20-
fold less tightly than3. This compound resembles the
structure of a very late transition state (Figure 2B) in which
the C-O bond is almost completely broken.
Transition state analogue inhibitors typically bind much
more tightly than the corresponding substrate does. The fact
that 3 binds only∼6-fold more tightly than1 may reflect
the fact that the reaction has a very early transition state with
little charge build-up on the oxirane oxygen. Taken together,
these observations suggest that3 can be viewed as a minimal
transition state inhibitor for FosA given that it lacks any of
the structural elements of the second substrate GSH.
Acetylphosphonate,4, with a neutral oxygen adjacent to
the phosphonyl group, has aKi that is significantly higher
than theKd for fosfomycin. This compound is of particular
interest because of its potential to form an enolate complex,
7, or a metal-stabilized 1,2-adduct with GSH,8.
The FosA‚Mn(II) complex does not catalyze exchange of
the methyl protons of4 in D2O (data not shown), suggesting
that the enzyme does not promote enolate formation over
and above that observed with Mn(II)‚6H2O. Inasmuch as4
is not a very good inhibitor, it is unlikely that8, if formed
on the enzyme, is a particularly stable or highly populated
species.
Escherichia colitransformed with the expression plasmid
for FosA exhibit robust resistance to fosfomycin. Unfortu-
nately, none of the inhibitors examined here were effective
in enhancing the efficacy of fosfomycin toward these
transformants either in liquid culture or on agar plates. The
reason for the lack of activityin ViVo is unclear but may be
due to ineffective transport of the molecules into the cytosol
of the bacterium.
Conclusions. The results reported here establish a stereo-
electronic basis for the design of effective inhibitors of
fosfomycin resistance proteins. The development of inhibitors
that are effectivein ViVo is an attractive avenue for enhancing
the efficacy of fosfomycin toward pathogens that harbor
either plasmid or genomically encoded resistance proteins.
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